This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Seattle Genetics' Adcetris Gets Breakthrough Therapy Status
by Zacks Equity Research
Seattle Genetics' (SGEN) Adcetris gets Breakthrough Therapy designation by the FDA for the frontline treatment of certain lymphoma subtypes.
Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug
by Zacks Equity Research
The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee vote for Mallinckrodt (MNK) abuse-deterrent drug.
Merck's Keytruda Improves Survival in Esophageal Cancer Study
by Zacks Equity Research
Merck's (MRK) Keytruda meets primary endpoint of overall survival in a phase III study evaluating it for the second-line treatment of advanced esophageal cancer.
Merck (MRK) Stock Moves -0.7%: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $74.09, moving -0.7% from the previous trading session.
AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study
by Zacks Equity Research
AbbVie's (ABBV) Mavyret demonstrates high virologic cure rates in a study evaluating it for an expanded patient population.
Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA
by Zacks Equity Research
PARP inhibitor makers get a boost following priority review for AstraZeneca???s (AZN) label expansion application for Lynparza as a first-line maintenance treatment for ovarian cancer.
Merck Starts Rolling BLA Submission for Ebola Vaccine V920
by Zacks Equity Research
Merck (MRK) begins the rolling submission of a BLA for its investigational Ebola vaccine candidate V920 to the FDA.
AstraZeneca's Lynparza Gets Priority Review in 1st Line Use
by Zacks Equity Research
AstraZeneca (AZN) and partner Merck's sNDA looking for label expansion of Lynparza in the first-line setting gets FDA's priority review.
Bayer (BAYRY) Beats on Q3 Earnings, Revenue Estimates
by Zacks Equity Research
Bayer (BAYRY) surpasses earnings and sales estimates in the third quarter of 2018 and reiterates outlook for 2018.
Merck's (MRK) Keytruda Gets FDA Approval for Liver Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda gains FDA approval for hepatocellular carcinoma (HCC) in patients previously treated with sorafenib.
Endo (ENDP) Stock Declines Despite Q3 Earnings & Revenue Beat
by Zacks Equity Research
Endo (ENDP) tops revenues and earnings expectations in the third quarter and raises its annual view. However, the results from the cellulite treatment trial are disappointing.
Catalyst (CPRX) Reports Q3 Loss as Expected & Pipeline Update
by Zacks Equity Research
Catalyst (CPRX) provides pipeline update and the FDA sets action date of Nov 28, 2018 for its lead pipeline candidate, Firdapse during the third quarter of 2018.
Keryx's (KERX) Loss Narrower Than Expected in Q3, Sales Lag
by Zacks Equity Research
Keryx's (KERX) sole marketed product generates sales of $26.6 million in the third quarter, up 96% from the year-ago quarter.
Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug
by Zacks Equity Research
Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $75.48 in the latest trading session, marking a +0.53% move from the prior day.
Agenus (AGEN) Q3 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Agenus (AGEN) reports a wider third-quarter loss. Revenues earned from collaborations exceeded expectations.
Horizon Pharma (HZNP) Q3 Earnings & Sales Beat, Shares Rise
by Zacks Equity Research
Shares of Horizon Pharma (HZNP) rise almost 16%, owing to record quarterly sales during the third quarter of 2018.
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in the third quarter of 2018. It expects to have cash to fund operations in 2021.
AstraZeneca's (AZN) Q3 Earnings Beat, New Drugs Drive Sales
by Zacks Equity Research
AstraZeneca (AZN) beats earnings and sales estimates in the third quarter and maintains previously issued outlook for 2018. AstraZeneca's newer medicines sales rise 86% in the quarter.
Perrigo (PRGO) Beats on Q3 Earnings, Cuts View, Shares Down
by Zacks Equity Research
Perrigo (PRGO) reports mixed third-quarter 2018 results and lowers revenue and adjusted earnings guidance for 2018 for the second straight quarter.
Democrats Hold Edge in House Battle: 5 Great Picks (Revised)
by Swarup Gupta
Drug and defense stocks would hugely benefit from a divided Congress.
Mallinckrodt (MNK) Beats on Q3 Earnings Estimates, Ups View
by Zacks Equity Research
Mallinckrodt (MNK) surpasses both earnings and sales estimates in the third quarter of 2018.
Beaten-Down Pharma ETFs to Buy Post Q3 Results
by Sweta Killa
Despite strong results, the broad market sell-off took the sheen from the pharma ETFs over the past month. These funds have a Zacks ETF Rank #2 (Buy), suggesting solid entry point on beaten down prices.
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo (PRGO) focuses on growth strategy for Consumer Healthcare Americas segment. The company plans to divest its loss-making Rx segment.
Democrats Hold Edge in House Battle: 5 Great Picks
by Swarup Gupta
Drug and defense stocks would hugely benefit from a divided Congress.